Product Name: Paclitaxel trevatide
Form: Free base
CAS No: 1075214-55-9
Molar Mass: 5109.36
Chemical Formula: C257H308N32O79
Synonyms: ANG1005
Storage: Store at -20℃
Sequence: {Paclitaxel-T}FFYGGSRG{Paclitaxel-K}RNNF{Paclitaxel-K}TEEY
Application:
Paclitaxel Trevatide (CAS: 1075214-55-9) is a novel therapeutic agent that combines paclitaxel, a widely used chemotherapy drug, with trevatide, a peptide-based compound. This innovative combination aims to enhance the effectiveness of paclitaxel in treating various types of cancer, including breast cancer, ovarian cancer, and lung cancer. Paclitaxel exerts its anti-cancer effects by inhibiting microtubule depolymerization, thereby disrupting cell division and inducing apoptosis (programmed cell death) in cancer cells. Trevatide, on the other hand, is designed to target specific receptors or proteins present on cancer cells, potentially enhancing the delivery of paclitaxel to tumor tissues and improving its efficacy. By combining these two agents, Paclitaxel Trevatide offers a synergistic approach to cancer treatment, with the potential to increase tumor response rates, prolong survival, and reduce adverse effects associated with conventional chemotherapy. Clinical trials are underway to evaluate the safety, efficacy, and therapeutic potential of Paclitaxel Trevatide in cancer patients, with the goal of providing new treatment options for individuals affected by these devastating diseases.
Current Research:
Paclitaxel Trevatide is an innovative therapeutic combination that merges the established anti-cancer activity of paclitaxel, a well-known chemotherapeutic agent, with the targeting capabilities of trevatide, a peptide or antibody-based drug conjugate (depending on the formulation). This combination aims to enhance the delivery and efficacy of paclitaxel by targeting tumor-specific markers, thereby improving the therapeutic index while reducing systemic toxicity.
Mechanism of Action
Paclitaxel is a microtubule-stabilizing agent that disrupts the normal function of the microtubules during cell division, leading to cell cycle arrest and apoptosis (programmed cell death). It has been used for decades to treat various solid tumors, including breast cancer, ovarian cancer, and non-small cell lung cancer (NSCLC). However, the efficacy of paclitaxel is often limited by its toxicity profile, which can cause significant side effects such as neutropenia, neuropathy, and cardiotoxicity.
Trevatide, on the other hand, is a targeting agent designed to enhance the delivery of paclitaxel specifically to tumor cells. It can be a peptide, antibody, or other targeting moiety that binds to tumor-specific antigens or receptors overexpressed on cancer cells. The conjugation of paclitaxel with trevatide allows for targeted delivery, meaning that paclitaxel is primarily delivered to the tumor tissue rather than to healthy cells, thereby reducing off-target effects and increasing the drug’s therapeutic efficacy.
This drug conjugate approach maximizes the cytotoxic potential of paclitaxel while minimizing the systemic toxicity typically associated with chemotherapy. The peptide or antibody component of trevatide binds to specific antigens or receptors on cancer cells, facilitating endocytosis and subsequent release of paclitaxel inside the tumor cells. This targeted delivery enhances the accumulation of paclitaxel in the tumor microenvironment, leading to increased anti-tumor activity.
Current Research and Development
Paclitaxel Trevatide is currently undergoing preclinical and early-phase clinical trials to assess its safety, pharmacokinetics, and efficacy in treating a variety of solid tumors, including breast cancer, ovarian cancer, and NSCLC. Early studies have shown promising results, particularly in improving the therapeutic window for paclitaxel.
A Phase 1 clinical trial investigating the safety and dosage of paclitaxel trevatide in cancer patients demonstrated that the combination of paclitaxel and trevatide was well-tolerated with a manageable side effect profile. Importantly, preclinical studies have suggested that the drug conjugate could significantly reduce the occurrence of common paclitaxel-related side effects, such as neuropathy and neutropenia, without compromising anti-tumor activity.
In addition, ongoing trials are focusing on evaluating the combination of paclitaxel trevatide with other immunotherapies, such as checkpoint inhibitors or monoclonal antibodies, to explore potential synergistic effects. The ability of trevatide to target specific tumor antigens may improve the efficacy of immunotherapies and help overcome resistance mechanisms in tumors that are not responsive to conventional treatments.
Advantages Over Conventional Chemotherapy
One of the primary advantages of Paclitaxel Trevatide over conventional paclitaxel therapy is its enhanced targeting ability. Traditional paclitaxel treatment has a broad systemic distribution, leading to toxicity in healthy tissues. By using trevatide to direct paclitaxel specifically to tumor cells, the drug conjugate reduces exposure to healthy tissues, thereby decreasing side effects like gastrointestinal distress, alopecia, and myelosuppression.
Another significant advantage is the potential for improved efficacy. The targeted nature of paclitaxel trevatide allows for more efficient delivery of the drug to the tumor microenvironment, which may enhance tumor cell death while preserving normal tissues. This targeted approach can also overcome certain forms of chemoresistance, which often develop in tumors that are no longer responsive to traditional chemotherapies due to poor drug penetration or drug efflux mechanisms.
Future Directions
Looking ahead, Paclitaxel Trevatide holds promise not only for enhancing treatment in common cancers but also for combination therapies with other cancer treatments, including immunotherapy and radiotherapy. Researchers are particularly focused on personalizing treatment by identifying tumor-specific biomarkers that can predict which patients will benefit most from this targeted approach.
Moreover, studies are expected to explore paclitaxel trevatide’s use in cancers that are more difficult to treat, such as triple-negative breast cancer (TNBC), ovarian cancers, and cancers with high levels of multidrug resistance (MDR). If successful, Paclitaxel Trevatide could offer a new, effective treatment option for patients with cancers that have limited treatment options.
The development of this drug conjugate represents a significant step forward in combining chemotherapy and targeted therapy into a single, more effective treatment regimen. With ongoing clinical trials and research into its use in combination with other therapeutic agents, paclitaxel trevatide may become an integral part of cancer treatment regimens in the near future.
Reference:
Get a Quote
LinkPeptide
